ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2559

Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis

Brooke Kelly1, Gregory Gamble1, Anne Horne1, Anthony Doyle1, Jill Drake2, Opetaia Aati1, Chang-Nam Son1, Ramanamma Kalluru3, Kieran Latto1, Lisa Stamp4 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, New Zealand, 3Health New Zealand, Auckland, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand

Meeting: ACR Convergence 2024

Keywords: gout, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Metabolic & Crystal Arthropathies

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of this study was to systematically examine the relationship between serum urate and changes in dual energy computed tomography (DECT) urate volume in people with gout and stable serum urate concentrations.

Methods: Individual participant data were analysed from three studies of people with gout. The time periods for the analysis were selected to identify study participants with serial DECT scans of both feet over a 12-month epoch of stable urate-lowering therapy and serum urate concentrations. Data from 251 study participants were analysed using a mixed-models analysis of covariance (ANCOVA) approach according to mean serum urate cut-points and mean serum urate bands. Study and first DECT urate volume were included in the models.

Results: For all mean serum urate cut-points assessed (4.0, 5.0, 6.0, 7.0 and 8.0 mg/dL), reductions in DECT urate volumes were observed below the cut-point (Figure). Significantly increased DECT urate volumes were observed at or above the 8.0mg/dL mean serum urate cut-point. Differences in the change in DECT volume were observed for the 7.0 mg/dL cut-point (P=0.0044) and the 8.0 mg/dL cut-point (P< 0.0001).  Significantly reduced DECT urate volumes were observed for the mean serum urate bands < 4.0 mg/dL and 4.0-4.9 mg/dL, and increased DECT urate volume was observed for the mean serum urate band ≥ 8.0 mg/dL (Table). For the mean serum urate bands 5.0-5.9, 6.0-6.9, 7.0-7.9 mg/dL, significant changes in DECT urate volumes were not observed.

Conclusion: The study findings support the concept that different serum urate targets may be appropriate at different stages of gout treatment. Serum urate bands below 5.0 mg/dL lead to MSU crystal dissolution over one year. Once MSU crystal dissolution is achieved, a higher target may be sufficient to prevent crystal formation; this study indicates that the higher target may be < 7.0 mg/dL. The study also provides empirical support for the EULAR recommendation of early use of urate-lowering therapy for patients with serum urate > 8.0 mg/dL, noting the increased MSU crystal volume at or above this level.

Supporting image 1

Supporting image 2


Disclosures: B. Kelly: None; G. Gamble: None; A. Horne: None; A. Doyle: None; J. Drake: None; O. Aati: None; C. Son: None; R. Kalluru: None; K. Latto: None; L. Stamp: Uptodate, 9; N. Dalbeth: Arthrosi, 2, AstraZeneca, 5, 6, Avalo Therapeutics, 2, Dexcel Pharma, 2, Hikma, 6, Horizon, 2, 6, JPI, 2, JW Pharmaceutical Corporation, 2, LG Chem, 2, Novartis, 6, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Shanton Pharma, 2, Sobi, 2, Unlocked Labs, 2.

To cite this abstract in AMA style:

Kelly B, Gamble G, Horne A, Doyle A, Drake J, Aati O, Son C, Kalluru R, Latto K, Stamp L, Dalbeth N. Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/relationship-between-serum-urate-and-changes-in-dual-energy-computed-tomography-msu-crystal-volume-over-one-year-in-people-with-gout-an-individual-participant-data-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-serum-urate-and-changes-in-dual-energy-computed-tomography-msu-crystal-volume-over-one-year-in-people-with-gout-an-individual-participant-data-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology